Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PECULIARITIES OF PURINE METABOLISM AND LIPID PEROXIDATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

https://doi.org/10.20996/1819-6446-2010-6-1-42-47

Full Text:

Abstract

Aim. To study purine metabolism and lipid peroxidation in patients with acute myocardial infarction with ST segment elevation (STEMI) in dependence on severity of acute heart failure (AHF). To evaluate effects of thrombolytic therapy on purine metabolism and lipid peroxidation.

Material and methods. 91 patients (age 60,8±1,2 y.o.) with STEMI and AHF (Killip 1-3) was included into the study. Patients were randomized into 3 groups in dependence of AHF severity. Markers of purine metabolism (activity of 5’- nucleotidase, xantineoxidase and uric acid level) and lipid peroxidation (superoxide dismutase and catalase activity, superoxide-anione radical level) were evaluated.

Results. Purine metabolism activity increases, antioxidant and prooxidant balance disturbs at the condition of energy deficiency. AHF progression leads to increase in xanthine oxidize activity, urinary acid level and lungs edematization. Thrombolytic therapy increases antioxidant activity (response on reperfusion), but does not lead to purine metabolism stabilization.

Conclusion. Thus, severity of heart failure in patients with STEMI correlates with disorders of purine and lipid metabolism. Thrombolytic therapy leads to rising in antioxidant protection, but does not lead to stabilisation of purine metabolism.

About the Authors

E. V. Horolets
Rostov State Medical University
Russian Federation
Nahichevansky per. 29, Rostov-on-Don, 344022


L. A. Haisheva
Rostov State Medical University
Russian Federation
Nahichevansky per. 29, Rostov-on-Don, 344022


S. V. Shlyk
Rostov State Medical University
Russian Federation
Nahichevansky per. 29, Rostov-on-Don, 344022


L. I. Katelnitskaya
Rostov State Medical University
Russian Federation
Nahichevansky per. 29, Rostov-on-Don, 344022


References

1. Оганов Р.Г., Масленникова Г.Я. Профилактика сердечно-сосудистых заболеваний — реальный путь улучшения демографической ситуации в России. Кардиология 2007;47(1):1-8.

2. Alderman M.H., Cohen H., Madhavan S., Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34(1):144-50.

3. Терещенко С.Н., Левчук Н.Н., Дроздов В.Н., Моисеев В.С. Уровень мочевой кислоты в крови больных с постинфарктной сердечной недостаточностью. Тер арх 2000;72(9):57-60.

4. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131(1):7-13.

5. Wannamethee S.G. Serum uric acid is not an independentrisk factor for coronary heart disease. Curr Hypertens Rep 2001;3(3):190-6.

6. Alderman M.H. Serum uric acid as a cardiovascular risk factor for heart disease. Curr Hypertens Rep 2001;3(3):184-9.

7. Høieggen A., Alderman M.H., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65(3):1041–9.

8. Johnson R.J., Kivlighn S.D., Kim Y.G. et al. Reappraisal ofthe pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999;33(2):225-34.

9. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82(1):47-95.

10. Гацуба С.В. Гацуба В.В. Проблемы регуляции кислородтранспортной функции крови в кардиологии. М.; 2005.

11. Биленко М.В. Ишемические и реперфузионные повреждения органов. М.: Медицина; 1989.

12. Комитет экспертов Всероссийского научного общества кардиологов. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Российские рекомендации. Кардиоваскулярная терапия и профилактика 2007;6(8 Приложение):1-66.

13. Карлов С.М., Колиушко Г.И., Сиротников Е.Л. Эффективность тромболитической терапии в острый период инфаркта миокарда у больных пожилого и старческого возраста. Український терапевтичний журнал 2002;(1):28-31.

14. Edwards N., Cassidy J., Fox I. Lymphocyte 5`-nucleotidase deficiency in hypogammaglobulinemia: clinical characteristics. Clin Immunol Immunopathol 1980;17(1):76-88.

15. Карпищенко А.И. Медицинские лабораторные технологии. Том 2. СПб: Интермедика; 1999.

16. Fried R. Enzymatic and non-enzymatic assay of superoxidedismutase. Biochimie. 1975;57(5):657-60.

17. Королюк М.А., Иванова Л.И., Майорова И.Г., Токарев В.Е. Метод определения активности каталазы. Лаб дело 1988;(1):16-9.

18. Арутюнян А.В., Дубинина Е.Е., Зыбина Н.Н. Методы оценки свободнорадикального окисления и антиоксидантной системы организма. Методические рекомендации. СПб.: ИКФ Фолиант; 2000.

19. Гланц С. Медико-биологическая статистика. М: Практика; 1999.

20. Меньщикова Е.Б., Зенков Н.К., Ланкин В.З. и соавт. Окислительный стресс: патологические состояния и заболевания.Новосибирск: АРТА; 2008.

21. Меньщикова Е.Б., Зенков Н.К., Ланкин В.З. и соавт. Окислительный стресс. Прооксиданты и антиоксиданты. М.: Слово; 2006.

22. Wamholtz A., Nickening G., Schultz E. et al. Increased NADH-oxidasemediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99(15):2027-33.


For citation:


Horolets E.V., Haisheva L.A., Shlyk S.V., Katelnitskaya L.I. PECULIARITIES OF PURINE METABOLISM AND LIPID PEROXIDATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2010;6(1):42-47. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-42-47

Views: 345


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)